Last Updated: November 16, 2026

ETCAMAH Drug Patent Profile

« Back to Dashboard


Which patents cover Etcamah, and what generic alternatives are available?

Etcamah is a drug marketed by Astrazeneca and is included in one NDA. There are six patents protecting this drug.

The generic ingredient in ETCAMAH is camizestrant. One supplier is listed for this compound. Additional details are available on the camizestrant profile page.

DrugPatentWatch® Generic Entry Outlook for Etcamah

Etcamah will be eligible for patent challenges on September 4, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 22, 2041. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ETCAMAH?
  • What are the global sales for ETCAMAH?
  • What is Average Wholesale Price for ETCAMAH?
Summary for ETCAMAH
US Patents:6
Applicants:1
NDAs:1

US Patents and Regulatory Information for ETCAMAH

ETCAMAH is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ETCAMAH is ⤷  Start Trial.

This potential generic entry date is based on patent 12,453,729.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca ETCAMAH camizestrant TABLET;ORAL 220359-001 Sep 4, 2026 RX Yes Yes 12,364,689 ⤷  Start Trial ⤷  Start Trial
Astrazeneca ETCAMAH camizestrant TABLET;ORAL 220359-001 Sep 4, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Astrazeneca ETCAMAH camizestrant TABLET;ORAL 220359-001 Sep 4, 2026 RX Yes Yes 10,590,130 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ETCAMAH

When does loss-of-exclusivity occur for ETCAMAH?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1922
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 21260109
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2022021089
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 79912
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 22002898
Estimated Expiration: ⤷  Start Trial

China

Patent: 5443128
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 22016378
Estimated Expiration: ⤷  Start Trial

Costa Rica

Patent: 220587
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 38787
Estimated Expiration: ⤷  Start Trial

Dominican Republic

Patent: 022000228
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 38787
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 38787
Estimated Expiration: ⤷  Start Trial

Guatemala

Patent: 2200239
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 7218
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 19796
Estimated Expiration: ⤷  Start Trial

Patent: 23522247
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 38787
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 0737
Estimated Expiration: ⤷  Start Trial

Patent: 22013258
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 388
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 221838
Estimated Expiration: ⤷  Start Trial

Philippines

Patent: 022552755
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 38787
Estimated Expiration: ⤷  Start Trial

San Marino

Patent: 02600361
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 517
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 2212663
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 230005270
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 80216
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 2206074
Estimated Expiration: ⤷  Start Trial

Patent: 93107
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ETCAMAH around the world.

Country Patent Number Title Estimated Expiration
Argentina 109951 ⤷  Start Trial
Australia 2017349797 ⤷  Start Trial
Brazil 112019007393 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ETCAMAH

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3433256 PA2026534 Lithuania ⤷  Start Trial PRODUCT NAME: KAMIZESTRANTAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOSPAVIDALU; REGISTRATION NO/DATE: EU/1/26/2046 20260720
3433256 C20265022 Finland ⤷  Start Trial
3433256 CA 2026 00044 Denmark ⤷  Start Trial PRODUCT NAME: CAMIZESTRANT, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTA; REG. NO/DATE: EU/1/26/2046 20260722
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.